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Abstract
Purpose: To investigate the clinical outcomes of stage I and IIA non-small cell lung cancer (NSCLC) patients treated
with stereotactic body radiotherapy (SBRT) using a real-time tumor-tracking radiotherapy (RTRT) system.
Materials and methods: Patterns-of-care in SBRT using RTRT for histologically proven, peripherally located, stage I
and IIA NSCLC was retrospectively investigated in four institutions by an identical clinical report format. Patterns-of-
outcomes was also investigated in the same manner.
Results: From September 2000 to April 2012, 283 patients with 286 tumors were identified. The median age was 78
years (52–90) and the maximum tumor diameters were 9 to 65 mm with a median of 24 mm. The calculated
biologically effective dose (10) at the isocenter using the linear-quadratic model was from 66 Gy to 126 Gy with a
median of 106 Gy. With a median follow-up period of 28 months (range 0–127), the overall survival rate for the
entire group, for stage IA, and for stage IB + IIA was 75%, 79%, and 65% at 2 years, and 64%, 70%, and 50% at 3
years, respectively. In the multivariate analysis, the favorable predictive factor was female for overall survival. There
were no differences between the clinical outcomes at the four institutions. Grade 2, 3, 4, and 5 radiation
pneumonitis was experienced by 29 (10.2%), 9 (3.2%), 0, and 0 patients. The subgroup analyses revealed that
compared to margins from gross tumor volume (GTV) to planning target volume (PTV) ≥ 10 mm, margins < 10 mm
did not worsen the overall survival and local control rates, while reducing the risk of radiation pneumonitis.
Conclusions: This multi-institutional retrospective study showed that the results were consistent with the recent
patterns-of-care and patterns-of-outcome analysis of SBRT. A prospective study will be required to evaluate SBRT
using a RTRT system with margins from GTV to PTV < 10mm.
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Background
Surgical resection is the standard of care for patients
with early stage non-small cell lung cancers (NSCLC).
However, patients with early stage NSCLC often cannot
tolerate surgical resection because of age and/or co-
morbidities such as chronic obstructive pulmonary and
cardiac diseases. With the advent of stereotactic body ra-
diation therapy (SBRT) and appropriate image-guidance
in the radiotherapy, it is now possible to administer very
high radiation doses to peripheral early stage NSCLC
over a short treatment time period without high risks of
complications [1–5]. Recent multivariable analysis has
shown improved overall survival with SBRT compared
with patients who received no treatment (hazard ratio,
0.64; p < .001) [6]. The SBRT is now recommended for
patients with early stage NSCLC who are medically in-
operable or refuse surgery [7]. Whether SBRT should be
the first choice of treatment for high risk patients rather
than surgical resection is still to be determined in a pro-
spective randomized trial [8–10].
Since inoperable early stage NSCLC patients often suf-
fer from poor respiratory functions, it is critically im-
portant to reduce the irradiated volume to normal lung
tissue in the treatment of lung tumors with SBRT, and
there have been many investigations to reduce the un-
certainty of tumor location due to respiration [11–14].
Inadequate respiratory motion management in SBRT has
been one of the causes of local recurrences [15]. Motion
management is essential in SBRT of lung tumors to be
able to deliver the treatment dose accurately. Four-
dimensional treatment planning, gating with a linear ac-
celerator, and real-time tracking of the internal tumor
motion have been shown to reduce the uncertainties due
to respiratory motion [16–18]. In 1999, a real-time
tumor-tracking radiotherapy (RTRT) system was devel-
oped and put into use for SBRT. This RTRT system uses
two sets of fluoroscopes in the treatment room for the
real-time tracking of the internal fiducial markers im-
planted in or near the lung tumor, tracking at 30 times a
second [18]. In the system, the linear accelerator is gated
to irradiate the tumor only when the implanted fiducial
marker is within 2 mm of the planned position which
has been determined in 4days treatment planning [19].
Although the RTRT system was introduced in several in-
stitutions in Japan and has been used for the SBRT of
early stage NSCLC for a decade, clinical results were
reported from only one institution [20–22] and no
multi-institutional clinical results of SBRT using the
RTRT system have been published.
The purpose of the present study is to evaluate clinical
results of SBRT for stage I and IIA NSCLC used with
this RTRT system in four institutions in Japan over the




We obtained written informed consent to administer
SBRT using the RTRT system from all patients and ap-
proval from the institutional review boards of all four in-
stitutions for this retrospective study. We reviewed
patients treated with SBRT using the RTRT system from
September 2000 to April 2012, diagnosed with histologi-
cally proven NSCLC and peripherally located clinical
stage I and IIA as determined by the seventh edition of
the Union for International Cancer Control staging cri-
teria. A peripherally located tumor was defined as a
tumor located outside a volume 2 cm in all directions
around the proximal bronchial tree. In principle, all the
patients with histologically proven, peripherally located,
stage I and IIA NSCLC were treated by SBRT using
RTRT in the four institutions during this period. Pa-
tients were excluded from the study if they had received
thoracic radiation therapy for simultaneous malignant
tumors within three months before or after the start
dates of the SBRT.
A total of 283 patients with 286 tumors were identi-
fied. The median age was 78 years (52–90). Among the
286 tumors, 155, 67, 41, and 23 tumors were treated in
the four institutions. The maximum tumor diameters
were from 9 to 65 mm with a median of 24 mm. Patient
characteristics are detailed in Table 1.
SBRT using an RTRT system
The RTRT system has been described in detail elsewhere
[19, 23]. In brief, the process for synchronizing the
tracking of a marker with the irradiation was as follows.
Before treatment, 1.5-mm or 2-mm gold markers were
implanted near the tumor by bronchoscopy, principally
within 5 cm of the center of the gross tumor volume
(GTV). After the insertion of the fiducial markers, com-
puted tomography was performed, usually while the
patient held the breath at the end of expiration. The
fluoroscopic RTRT system consists of four sets of diag-
nostic fluoroscopic, image-processor units, a trigger-
control unit, an image-display unit, and a conventional
linear accelerator with multileaf collimators. The linear
accelerator is gated to irradiate the tumor only when the
gold marker is within 2.0 mm of the planned coordinates
relative to the isocenter in the lateral, craniocaudal, and
anterior-posterior directions.
Patterns-of-care in SBRT using RTRT was retrospect-
ively investigated in the four institutions. To evaluate
the radiation dose, the biologically effective dose (BED)
was calculated using the linear-quadratic model, de-
fined as nd*(1 + d/(α/β)), where n is the number of
fractions and d is the dose per fraction, assuming an
α/β of 10 for tumors.
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Evaluation
Follow-up examinations and computed tomography (CT)
scans were commonly performed every 3 to 6 months
after the SBRT. The definition of local failure was as fol-
lows: sequential enlarging opacity for more than 6 months
on CT images, enlarging opacity corresponding to FDG-
PET abnormalities and/or histologic confirmation.
Absence of local disease recurrence was defined as a lo-
cally controlled disease. Toxicities were assessed with
Common Terminology Criteria for Adverse Events v3.0.
Statistical analysis
The follow-up duration was calculated from the start
date of the SBRT. The Kaplan-Meier method was used
for calculating overall survival (OS) and local control
(LC) rates. The log-rank test was used to compare sub-
groups. Multivariate analysis was performed using a Cox
proportional hazards regression model. The hazard ratio
(HR), 95% confidence interval (95%CI), and p value were
calculated. The rates for Grade 2 or higher radiation
pneumonitis were compared in subgroups using the uni-
variate and multivariate logistic regression analyses
where the odds ratio (OR) and 95%CI were estimated. A
p value of < 0.05 was considered statistically significant.




Patterns-of-care in SBRT using RTRT are shown in
Table 2. For the clinical target volume (CTV) margins, a
margin of 0 mm was most frequently used. One institu-
tion usually adopted a CTV margin of 6 to 8 mm added
to the GTV uniformly to include the microscopic tumor
spread based on Giraud et al.’s report [24]. In another
institution, a part of the GTV was expanded manually to
ensure that the CTV included the tumor spiculations,
which were not visualized on the planning CT images,
but appeared on the diagnostic high-resolution CT im-
ages. Thus, all of 9 mm or wider CTV margins were de-
lineated non-uniformly and adopted only in this
institution, and were the maximum distance between
the GTV and CTV contours. For the planning target vol-
ume (PTV) margin, which is comprised of the internal
and the set-up margins, a margin of 5 mm was most fre-
quently used. It varied from 3 to 12 mm depending on
patient condition, the visibility of fiducial markers, and
other factors. All SBRT plans were generated using
three-dimensional conformal treatment planning tech-
niques with a median of 6 static ports (range, 4–9).
Thirty-nine treatment plans were calculated using the
Clarkson method and 247 treatment plans used the
Superposition method. A total dose of 35–60 Gy was ad-
ministered in 4–9 fractions. The dose was prescribed at
the isocenter in 189 treatment plans and the most fre-
quent schedule was 48 Gy in 4 fractions in 149 treat-
ment plans. The dose was prescribed for the 95%
volume of the PTV (PTVD95) in 97 treatment plans and
the most frequent schedule was 40 Gy in 4 fractions in
94 treatment plans. Among 286 treatment plans, a total
of 234 treatment plans (137 prescribed at the isocenter




Median 78 (range 52–90) 79 (52–89) 77.5 (52–90)
Gender
Male 214 124 74
Female 69 61 6
Performance status
0 58 40 13
1 184 124 51
2 37 19 14
3 3 1 2
Unknown 1 1 0
Observation period (months)
Median 28 (range 0–127) 30 (0–127) 25 (2–101)
Institutions
A 155 97 45
B 67 47 16
C 41 25 14
D 23 16 5
Maximum tumor diameter (mm)
Median 24 (range 9–65) 23 (9–65) 26 (13–65)
Number of tumors
1 280 - -
2 3 - -
T stage
1a and 1b 195 131 51
2a and 2b 91 54 29
Tumor location
Right Upper Lobe 74 54 15
Right Middle Lobe 18 10 7
Right Lower Lobe 69 45 21
Left Upper Lobe 75 47 24
Left Lower Lobe 50 29 13
Operability
Operable 71 49 16
Inoperable 190 120 55
Unknown 25 16 9
SCC squamous cell carcinoma
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and 97 prescribed to the PTV D95) were available for ana-
lysis of the dose to the PTVD95. The calculated BED (10)
at the isocenter using the linear-quadratic model was from
66 Gy to 126 Gy with a median of 106 Gy in 286 treat-
ment plans. The BED (10) to the PTVD95 was from 44 Gy
to 106 Gy with a median of 80 Gy in 234 treatment plans.
Overall survival and Local control
The median follow-up period was 28 months (range, 0–
127). In the 283 patients, the OS rates for all patients,
stage IA, and stage IB + IIA were 75%, 79%, and 65% at
2 years, and 64%, 70%, and 50% at 3 years, respectively
(Fig. 1). There was no significant difference in OS rates
among institutions. The results of the univariate analysis
of OS rates are shown in Table 3. There was a statisti-
cally significant difference in the OS rates between the
subgroups with females and males (3-year: 83% and 58%,
respectively; p = 0.0016).
In the 286 tumors, the LC rates for all tumors, T1a +
T1b, and T2a + T2b tumors were 81%, 84%, and 74% at 2
years, and 75%, 79%, and 64% at 3 years (Fig. 2). There
were no significant differences in the LC rates among in-
stitutions. The results of the univariate analysis of LC rates
are shown in Table 4. There was a statistically significant
difference in the LC rates between the subgroups with
BED (10) at the isocenter ≥ 90Gy and BED (10) < 90 Gy
(3-year: 78% and 42%, respectively; p = 0.0001), but no sig-
nificant difference between BED (10) ≥ 100 Gy at the iso-
center and BED (10) < 100 Gy (3-year: 74% and 76%,
respectively; p = 0.8987, not listed in Table 4). There were
no significant differences in the LC rates between BED
(10) ≥ 80 Gy to the PTVD95 and BED (10) < 80 Gy (3-year:
81% and 72%, respectively; p = 0.1963, not listed in
Table 4). Adenocarcinomas also showed more favorable
LC rates than squamous cell carcinomas (SCC) (3-year:
80% and 62%, respectively; p = 0.0002). There were no
Table 2 Patterns-of-care in SBRT using RTRT
n Adenocarcinoma SCC
Number of ports
4 2 1 1
5 89 64 21
6 173 101 56
7 17 14 2
8 4 4 0
9 1 1 0
X-ray energy (MV)
4 4 4 0
6 231 148 64
10 51 33 16
CTV margin (mm)
0 140 94 33
5 3 0 3
6 32 2 30
7 5 2 0
8 84 71 9
9 5 3 2
10 4 3 0
11 12 10 2
12 1 0 1
PTV margin (mm)
3 67 47 16
5 112 70 34
7 17 11 4
8 74 47 22
10 11 6 3
12 1 1 0
unclassifiable 4 3 1
Margin from GTV to PTV (mm)
0–4 67 47 16
5–9 57 37 13
10–14 110 66 38
15– 48 32 12
unclassifiable 4 3 1
Calculation algorithms
Clarkson 39 29 10
Superposition 247 156 70
Prescription
PTVD95 97 59 27
Isocenter 189 126 53
Dose (Gy/Fr)
Prescription: PTVD95
40/4 94 56 27
Table 2 Patterns-of-care in SBRT using RTRT (Continued)
others 3 3 0
Prescription: Isocenter
48/4 149 99 42
50/5 19 13 4
others 21 14 7
BED (10) at the Isocenter (Gy)
≥ 100 205 134 55
< 100 81 51 25
BED (10) at the Isocenter (Gy)
≥ 90 267 173 74
< 90 19 12 6
BED biologically effective dose, CTV clinical target volume, Fr fractions, GTV
gross tumor volume, Gy gray, MV megavoltage, PTV planning target
volume, RTRT real-time tumor-tracking radiotherpay, SBRT stereotactic
body radiotherapy
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significant differences in the OS and LC rates between
margins from GTV to PTV ≥ 10 mm and margin < 10
mm, and also no significant differences in the OS and LC
rates among the upper/middle and the lower lobes.
In the multivariate analysis, all clinical factors showed
similar trends to those in the univariate analysis. In the
OS rate, gender was a significant predictive factor (HR
2.393, 95%CI [1.380–4.418], p = 0.0015, Table 3). In the
LC rate, significant factors were histology (HR 2.366,
95%CI [1.311–4.301], p = 0.0044) and BED (10) of 90 Gy
at the isocenter (HR 3.465, 95%CI [1.656–6.706], p =
0.0017), respectively (Table 4).
Fiducial marker insertion
Among the 286 procedures of the fiducial marker inser-
tions, data were available for 280 procedures. The num-
ber of fiducial markers implanted in each patient was
from 1 to 7 (median: 4). The number of fiducial markers
at the start date of the SBRT was from 1 to 6 (median:
4). At the start date of the SBRT there were 918 fiducial
markers out of a total of 1100 inserted. During the treat-
ment, replanning was required in 3 patients due to
inter-fractional migration of fiducial markers. Pneumo-
thorax related to the insertion of the fiducial markers
was observed in 3 patients (Grade 1: one patient, Grade
2: two patients). One patient showed Grade 2 tachycar-
dia. No patients experienced Grade 3 or higher
complications.
Radiation pneumonitis
The median of the PTV was 52.4 cc (5.7–313 cc) in
the 252 plans which were available for analysis. Lung
volume was defined as the bilateral lung volume
minus the PTV volume. The median of the lung vol-
umes was 3093 cc (1325–6886 cc) in the 257 plans.
The median of the mean lung dose (MLD) was 355
Fig. 1 Overall survival rates in all patients (a), patients with stage IA and with stage IB + IIA (b), respectively
Table 3 Univariate and multivariate analysis results of overall survival rates
Variables Overall Survival Rates Univariate Analysis Multivariate Analysis
n 2-year 3-year p-value HR (95%CI) p-value
Stage IA 193 79 70 0.0348 - 0.0693
IB + IIA 90 65 50 1.484 (0.968–2.242)
Histology Adenocarcinoma 184 79 69 0.0689 - 0.5293
SCC 79 69 52 1.151 (0.737–1.772)
Gender Female 69 86 83 0.0016 - 0.0015
Male 214 71 58 2.393 (1.380–4.418)
Location Upper and Middle 165 76 65 0.925 - 0.9900
Lower 118 73 62 0.997 (0.660–1.489)
BED (10) IC (Gy) ≥ 90 264 75 65 0.4428 - 0.6830
< 90 19 68 56 1.145 (0.570–2.083)
Margins from GTV to PTV (mm) ≥ 10 156 72 63 0.3268 - 0.6307
< 10 123 77 64 0.904 (0.596–1.355)
BED biologically effective dose, CI confidence interval, GTV gross tumor volume, HR hazard ratio, IC isocenter, OS overall survival, PTV planning target volume, SCC
squamous cell carcinoma
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cGy (101–996 cGy) in 239 plans. The median of the
percentage of lung volume receiving a dose of 5 Gy
or more (V5) and a dose of 20 Gy or more (V20)
were 19.7% (6.2–45.4%) in 228 plans and 5.0% (1.0–
16.0%) in 246 plans, respectively.
Radiation related pneumonitis with the SBRT could be
assessed for 275 treatments. Nine patients had Grade 3
radiation pneumonitis. Grade 2 or higher radiation
pneumonitis were observed in 38 patients (Grade 2: 29,
Grade 3: 9). No patients experienced Grade 4 or 5 radi-
ation pneumonitis. One of nine patients with Grade 3
radiation pneumonitis developed Grade 5 infectious
pneumonia. This male patient received 40 Gy to the
PTVD95 in 4 fractions for a 2.5 cm diameter tumor at
the left upper lobe. Here MLD, V5 and V20 were 494
cGy, 23.7% and 10.1%, respectively. This patient experi-
enced Grade 3 radiation pneumonitis 2 months after the
SBRT. Although the radiation pneumonitis was
improved by steroid therapy, the patient subsequently
developed cytomegalovirus pneumonia 4 months after
the SBRT and passed away, likely due to immunosup-
pression caused by the steroids.
The results of the univariate and multivariate analyses
of the rates of radiation pneumonitis are shown in
Table 5. Among the 271 treatments in which it was pos-
sible to evaluate both radiation pneumonitis and mar-
gins from GTV to PTV, Grade 2 or higher radiation
pneumonitis was observed in 32 (21.2%) of 151 treat-
ments with margins from GTV to PTV ≥ 10 mm, and
there were 5 (4.2%) of 120 treatments with margins < 10
mm. In the univariate analysis, a statistically significant
difference was observed in the rates of Grade 2 or higher
radiation pneumonitis between these two subgroups.
There was also a statistically significant difference
observed between the subgroups with BED (10) at the
isocenter ≥ 90 Gy and BED (10) < 90 Gy (14.8% vs. 0.0%,
Fig. 2 Local control rates of all tumors (a), T1a + T1b tumors and T2a + T2b tumors (b), respectively
Table 4 Univariate and multivariate analysis results of local control rates
Variables Local Control Rates (%) Univariate Analysis Multivariate Analysis
n 2-year 3-year p-value HR (95%CI) p-value
T stage T1a + T1b 195 84 79 0.1263 - 0.5903
T2a + T2b 91 74 64 1.173 (0.647–2.076)
Histology Adenocarcinoma 185 87 80 0.0002 - 0.0044
SCC 80 65 62 2.366 (1.311–4.301)
Gender Female 69 88 85 0.0595 - 0.2307
Male 217 79 71 1.595 (0.751–3.700)
Location Upper and Middle 167 82 76 0.8487 - 0.8845
Lower 119 79 73 1.042 (0.591–1.808)
BED (10) IC (Gy) ≥ 90 267 84 78 0.0001 - 0.0017
< 90 19 49 42 3.465 (1.655–6.706)
Margins from GTV to PTV (mm) ≥ 10 158 81 71 0.8043 - 0.8723
< 10 124 80 78 1.047 (0.589–1.833)
BED biologically effective dose, CI confidence interval, GTV gross tumor volume, HR hazard ratio, IC isocenter, LC local control, PTV planning target volume, SCC
squamous cell carcinoma
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p = 0.0154), but no significant difference between BED
(10) ≥ 100 Gy at the isocenter and BED (10) < 100 Gy
(14.7% vs. 11.5%, p = 0.4839, not listed in Table 5). In the
multivariate analysis, significant risk factors for Grade 2
or higher radiation pneumonitis were GTV to PTV mar-
gin ≥ 10 mm (OR 6.479, 95% CI [2.558–19.988], p <
0.0001), BED (10) at the isocenter ≥ 90 Gy (OR not
estimable (NE), 95%CI [1.803–NE], p = 0.0118) and
lower lobe tumors (OR 2.281, 95%CI [1.042–5.063], p =
0.0392), respectively (Table 5).
Other treatment related toxicities
One patient experienced Grade 3 dermatitis, and 10
patients reported Grade 2 thoracic wall pain. No other
toxicities were recorded.
Discussion
Guckenberger et al. have pointed out that image-
guidance, gating, and real-time tracking can improve ac-
curacy in pulmonary stereotactic body radiotherapy [25].
They investigated the required safety margins in SBRT
by pre- and post-treatment cone-beam CT imaging in
43 patients, and found that stereotactic patient position-
ing and image-guidance based on the bony anatomy re-
quired safety margins of 12 mm and 9 mm, respectively.
Four-dimensional image-guidance targeting of the tumor
itself and intra-fractional tumor tracking made it possible
to reduce margins to < 5 mm and < 3 mm, respectively.
That study suggested that additional safety margins are re-
quired to compensate for breathing motion. Shimizu et al.
and others have shown that the RTRT system can reduce
the additional PTV margins for interfractional as well as
intrafractional target motion taking account of baseline
shift/drift and fluctuations in the amplitude during the
treatment [12, 13, 26].
Inoue et al. have reported the experience with RTRT
in a single institution where the 5-year LC rate was 78%
and the 5-year OS rate was 64% for 109 patients (79
T1N0M0 and 30 T2N0M0) with a median follow-up
period of 25 months (range, 4 to 72 months) [20]. In the
present multi-institutional retrospective study, the OS
rates for Stage I and IIA NSCLC were 75% and 64% at 2
and 3 years respectively. This is consistent with the 70%
(95% CI: 67–72%) OS rates at 2 years for 3201 patients
in a systematic review [27] and a 47% 3-years OS of 582
patients in the recent patterns-of-care and patterns-of-
outcome analysis of SBRT for Stage I NSCLC [28].
A recent review article summarized the LC rates of
SBRT for Stage I NSCLC and showed that the 3-year local
control rates were widely distributed, from 40% to 92%, in
studies which had a longer than 2-year follow-up [29].
The wide variation in LC rates may be ascribed to the dif-
ficulty of ensuring a uniform definition of LC because of
the radiological changes after SBRT for periods of years
[30]. The LC rates for Stage I and IIA NSCLC was 75% at
3 years in this series. This is consistent with the recent
patterns-of-care and patterns-of-outcome analysis which
showed 3-years of freedom from local progression of
79.6% [28]. A significant difference in the LC rate was
found at a BED (10) of 90 Gy at the isocenter but not at
100 Gy or higher. The threshold for a high LC in the previ-
ous studies of SBRT for stage I NSCLC has been reported
to be 100 Gy or higher in BED (10) at the isocenter [4].
A recently published report, in which local tumor con-
trol probability (TCP) in SBRT was evaluated, showed
that a strong dose–response relationship was observed
in the primary NSCLC and the dose to achieve 90% TCP
Table 5 Univariate and multivariate analysis results of Grade 2 or higher radiation pneumonitis rate
Variables Grade 2≥ Radiation Pneumonitis Univariate Analysis Multivariate Analysis
n Rates (%) OR (95%CI) p-value OR (95%CI) p-value
T stage T1a + T1b 189 13.2 Reference - Reference -
T2a + T2b 86 15.1 1.168 (0.552–2.377) 0.6760 1.381 (0.590–3.121) 0.4485
Histology Adenocarcinoma 177 15.3 1.553 (0.698–3.817) 0.2902 1.492 (0.608–3.963) 0.3896
SCC 77 10.4 Reference - Reference -
Gender Female 69 15.9 1.257 (0.567–2.632) 0.5600 1.298 (0.525–3.099) 0.5643
Male 206 13.1 Reference - Reference -
Location Upper and Middle 160 11.3 Reference - Reference -
Lower 115 17.4 1.661 (0.834–3.329) 0.1481 2.281 (1.042–5.063) 0.0392
BED (10) IC (Gy) ≥90 256 14.5 NE (1.593–NE) 0.0154 NE (1.803–NE) 0.0118
<90 19 0.0 Reference - Reference -
Margins from GTV to PTV (mm) ≥10 151 21.2 6.185 (2.530–18.579) <0.0001 6.479 (2.558–19.988) <0.0001
<10 120 4.2 Reference - Reference -
BED biologically effective dose, CI confidence interval, GTV gross tumor volume, HR hazard ratio, IC isocenter, NE not estimable, PTV planning target volume,
SCC squamous cell carcinoma
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was BED (10) at the isocenter > 176 Gy [31]. According
to the dose response curve demonstrated in that report,
BED (10) of 90 Gy at the isocenter would result in a
local control of about 75%, matching the results of this
study. As both BED (10) of 90 Gy and 100 Gy were in
the steep part of the dose response curve, the difference
between the threshold for LC BED (10) of 90 Gy in this
study and 100 Gy in Onishi et al.’s report [4] could arise
from differences in heterogeneity (tumor, patients, treat-
ment and other factors) between these studies.
In our multivariate analysis, female was a significant
predictive factor for OS and adenocarcinoma was signifi-
cant for the LC rate. It is still not commonly agreed
whether tumor histology is related to clinical outcomes
in NSCLC treated with SBRT. Some studies have re-
ported an absence of statistically significant differences
in the survival or recurrence rates of adenocarcinomas
and SCC [32, 33]. Matsuo et al. analyzed 101 patients
with histologically confirmed stage I NSCLC who under-
went SBRT [34], and reported that females had a signifi-
cantly better prognosis than males and that histology
was less significant. They suggested that this result may
be caused by the proportion of lung adenocarcinomas in
females being higher than in males. In our study, the
situation was similar, with female patients having a
significantly higher proportion of adenocarcinomas
(Additional file 1) and a higher OS rate than males. In
the LC rate, gender differences were not statistically
significantly different but adenocarcinoma was a statisti-
cally significant predictive factor. One possible explan-
ation for this is that gender differences in tumor
histology may result in higher survival rates in females
and higher LC rates in adenocarcinomas. Future study
will be needed to further investigate the relationships
between gender and tumor histology.
The potential benefit of the RTRT system strongly de-
pends on the reproducibility of the position of the
marker and the target volume. The relationship between
the marker and the tumor position has been investigated
in detail. As there is a learning curve for the insertion of
fiducial markers through bronchial fiberscopy [14, 35] a
strictly observed verification routine before treatment is
mandatory [36], clinical training of the pulmonologists
and radiation oncologists must be conducted in all insti-
tutions which install the RTRT system. The present
study showed that there were no differences in the OS
and LC rates among the different institutions. This ab-
sence of differences does not preclude a dependence of
the clinical outcome on the insertion techniques but is
encouraging and implies that any effect of a learning
curve is minimal provided that proper training of the
staff is available.
The distance between the fiducial marker and the tar-
get volume may change more in the lower lobe than in
the middle or upper lobes during irradiation [37]. How-
ever, we did not see any difference in the OS and LC
rates among the upper, middle, and lower lobes. Again
here, any similarity in the OS and LC rates does not pre-
clude a dependence of the clinical outcome to arise from
differences in the location of the tumor but the effect as
determined in this study is suggested to be minimal.
It is well known that the risk of radiation pneumonitis
is correlated to the mean lung dose or other parameters
which are related to dose volume statistics [38–43]. The
RTRT is expected to reduce the volume of normal lung
tissue which receives radiation doses that could give rise
to the development of radiation pneumonitis. In the
present study, Grade 2, 3, 4, and 5 radiation pneumonitis
was experienced by 29 (10.2%), 9 (3.2%), 0, and 0 pa-
tients, respectively among 283 patients. Inoue et al. have
reported the RTRT experience in a single institution and
found that Grade 2, 3, 4, and 5 radiation pneumonitis
was experienced by 15 (13.8%), 3 (2.8%), 0, and 0 pa-
tients, respectively in 109 patients [20]. In a Japanese
multi-institutional prospective trial of SBRT 48 Gy was
prescribed at the isocenter in 4 fractions for T1N0M0
NSCLC [5], the Grade 3, 4, and 5 radiation pneumonitis
incidence was as follows: 9 (5.9%), 1 (0.6%), and 0 pa-
tients, respectively in 169 patients (Grade 2 incidence
was data not shown). Although attention must be paid
to compare the results from a retrospective study with
those from a prospective study, the low complication
rate in this study is consistent with other SBRT studies.
We have however seen one (0.3%) Grade 5 adverse
event, which is consistent with the Nagata et al. report
in which there were 14 (0.6%) Grade 5 complications
among 1111 patients who were treated with lung SBRT
[44]. Since the complication rate has been reported to be
very low in other SBRT studies, it is not certain whether
RTRT was effective to reduce the complication rate
below that of other SBRT technologies. Subgroup ana-
lyses demonstrated that there were no significant differ-
ences in the OS and the LC rates between margins from
GTV to PTV ≥ 10 mm and margins < 10 mm, whereas
the subgroup with margins ≥ 10 mm showed higher rate
of Grade 2 or higher radiation pneumonitis. A prospect-
ive study will be required to determine whether RTRT
with margins from GTV to PTV < 10mm would allow
increasing the dose to the tumor and reduce the risk of
radiation pneumonitis.
Conclusions
This multi-institutional retrospective study of SBRT
using a RTRT system for stage I and IIA NSCLC showed
that the OS and LC rates were consistent with the recent
patterns-of-care and patterns-of-outcome analysis of
SBRT. The subgroup analyses revealed that smaller mar-
gins from GTV to PTV did not worsen the OS and the
Katoh et al. Radiation Oncology  (2017) 12:3 Page 8 of 10
LC rates, while reducing the risk of radiation pneumon-
itis. A prospective study will be required to evaluate
SBRT using an RTRT system with margins from GTV to
PTV < 10mm.
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